CA9 and inflammatory breast carcinoma: The endogenous hypoxia marker CA IX was expressed in only 46% of the IBC patients, while it was expressed in 68% of non-IBC patients with unfavourable prognosis (P=0.047) and in 45% of non-IBC patients with favourable prognosis.